At Policlinico Universitario Agostino Gemelli IRCCS in Rome, Dr. Elisabetta Perrone is offering patients with aggressive neuroendocrine tumors a lifeline that didn't exist just months ago—a novel radiopharmaceutical therapy that targets cancer cells with precision while sparing healthy tissue.
Neuroendocrine tumors, which originate in hormone-producing cells scattered throughout the gastrointestinal tract, pancreas, and lungs, are notoriously difficult to treat, especially once they've metastasized and patients have exhausted conventional options. For those whose disease progresses despite chemotherapy, surgery, and standard radiation therapies, the prognosis has historically been poor and hope limited. This is where the new approach—using a compound called 225Ac-DOTA-LM3—changes the equation.
The therapy represents a shift in how doctors fight these cancers. Rather than using beta-emitting radiation that travels widely through tissue, 225Ac-DOTA-LM3 employs alpha particles, which deliver high-energy radiation over extremely short distances. This precision means the treatment can target tumor cells that express somatostatin receptors while minimizing damage to surrounding healthy organs—a critical balance in systemic cancer therapy.
Dr. Perrone and her team treated twenty patients with grade 3 neuroendocrine tumors at CURANOSTICUM Wiesbaden-Frankfurt under the supervision of Dr. Richard P. Baum. Some received the treatment as standalone therapy across nine cycles; others received it in tandem with a beta-emitting nuclide in thirty-two cycles. What happened next offers genuine encouragement. One patient achieved complete remission—the disease disappeared entirely. Ten more experienced partial remission, meaning their tumors shrank significantly. Two patients' disease remained stable. The treatment itself proved remarkably well-tolerated, with only mild, self-limiting side effects like nausea. Long-term complications, when they occurred, were relatively modest: anemia, reduced white blood cell counts, and decreased platelets.
"It can be very challenging to treat these patients as they have already received many different types of therapies," Perrone explained, underscoring why this development matters. After patients have already undergone chemotherapy, PRRT with 177Lu-DOTATATE, hormone therapy with Lanreotide, and other interventions—as in the documented case of a 58-year-old pancreatic neuroendocrine tumor patient with spreading to liver and bone—conventional options dry up. Alpha-PRRT offers a meaningful alternative.
At the time of analysis, eleven patients were alive with a median follow-up of seven months. Nine patients had died, with a median survival of eighteen months—a meaningful extension for those facing otherwise terminal diagnoses. While these numbers reflect a small, heterogeneous group treated in specialized centers under careful monitoring, they hint at what broader application might achieve.
The catch: 225Ac-DOTA-LM3 remains investigational and is currently available only at highly specialized centers like those in Germany where this study was conducted. Before the therapy can reach a wider patient population, larger multicenter studies and prospective clinical trials must confirm its efficacy, define safety parameters more precisely, optimize dosing, and identify which patients stand to benefit most.
Dr. Baum's path forward is clear: expand access carefully through rigorous science. For neuroendocrine tumor patients today who have nowhere left to turn, this novel therapy represents not a cure, but something almost as valuable—a genuine second chance.